Market News & Trends
Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation
Cue Biopharma, Inc. recently announced the company’s therapeutic Immuno-STAT (Selective Targeting and Alteration of T cells) platform is scheduled to be featured in a Merck…
leon & Nucleus Medical Announce Collaboration to Develop & Manufacture Novel Transplantation Medicine
This license agreement enables Nucleus to utilize proprietary MicroJet Reactor (MJR) nanotechnology to improve stability, increase solubility and enhance bioavailability of its lead asset in…
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
Aravive, Inc. recently announced that the independent Data Monitoring Committtee (DMC) has reviewed the open-label data following the first 28-day treatment cycle for the three…
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial
Mustang Bio, Inc. recently announced that the first subject treated with the optimized MB-106 (CD20-targeted, autologous CAR T cell therapy) manufacturing process, developed in collaboration…
Diasome Announces Positive Results from Phase 2 OPTI-1 Study
Diasome Pharmaceuticals, Inc. recently announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to mealtime insulin in people with…
Annovis Issued Patent for Method of Treating Parkinson’s Disease & Other Lewy Body Diseases
Annovis Bio Inc. was recently issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia, and other…
Copley Scientific Introduces Simple Device for Inhaled Dose Dissolution Testing
The new Inhaled Dissolution Dose Collector (IDDC) from Copley Scientific is a flexible, easy-to-use system for collecting the respirable fraction of the dose delivered by…
Cocrystal Pharma’s Structure-Based Technology Demonstrated Broad Utility
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics using its proprietary structure-based drug discovery platform technology to create first-and…
Oculis Announces Positive OCS-01 Phase 2 Data
Oculis S.A. recently reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment…